SELLAS Life Sciences Group, Inc.
SLS
$1.82
-$0.09-4.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.29% | -36.97% | 16.27% | -16.38% | -22.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.81% | -37.14% | -1.94% | -21.71% | -15.79% |
| Operating Income | 9.81% | 37.14% | 1.94% | 21.71% | 15.79% |
| Income Before Tax | 11.63% | 39.23% | 17.20% | 23.30% | 15.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.63% | 39.23% | 17.20% | 23.30% | 15.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.63% | 39.23% | 17.20% | 23.30% | 15.50% |
| EBIT | 9.81% | 37.14% | 1.94% | 21.71% | 15.79% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 48.30% | 68.99% | 65.51% | 68.15% | 58.43% |
| Normalized Basic EPS | 48.27% | 68.97% | 59.90% | 68.14% | 58.44% |
| EPS Diluted | 46.15% | 68.99% | 65.51% | 68.15% | 58.31% |
| Normalized Diluted EPS | 48.27% | 68.97% | 59.90% | 68.14% | 58.44% |
| Average Basic Shares Outstanding | 71.02% | 95.84% | 140.18% | 140.71% | 103.30% |
| Average Diluted Shares Outstanding | 71.02% | 95.84% | 140.18% | 140.71% | 103.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |